BACKGROUND: To develop novel therapeutic approaches for patients with head and neck malignancies, poorly immunogenic murine models of squamous cell carcinoma (SCC) need to be defined. METHODS: The phenotype, growth characteristics, and responsiveness to tumor-specific T-cell transfer of a spontaneously arising murine SCC (SCC VII) were characterized. RESULTS: SCC VII expresses major histocompatibility complex (MHC) class I molecules yet is resistant to tumor-specific T-cell killing and relatively insensitive to killing mediated by lymphokine-activated killer (LAK) cells. Intradermal tumors are reproducibly established after vaccination of 5 x 10(4) cells, and systemic micrometastases are apparent after intravenous administration of 2.5 x 10(4) cells. Immunotherapy of 3-day lung metastases using tumor-specific T cells and systemic interleukin-2 (IL-2) was ineffective in reducing the number of metastases in vivo. CONCLUSIONS: SCC VII is a poorly immunogenic murine squamous cell cancer, which represents an ideal model for preclinical testing of immunotherapeutic approaches for patients with SCC of the upper aerodigestive tract. Copyright 2001 John Wiley & Sons, Inc. Head Neck 23: 899-906, 2001.
BACKGROUND: To develop novel therapeutic approaches for patients with head and neck malignancies, poorly immunogenic murine models of squamous cell carcinoma (SCC) need to be defined. METHODS: The phenotype, growth characteristics, and responsiveness to tumor-specific T-cell transfer of a spontaneously arising murineSCC (SCC VII) were characterized. RESULTS:SCC VII expresses major histocompatibility complex (MHC) class I molecules yet is resistant to tumor-specific T-cell killing and relatively insensitive to killing mediated by lymphokine-activated killer (LAK) cells. Intradermal tumors are reproducibly established after vaccination of 5 x 10(4) cells, and systemic micrometastases are apparent after intravenous administration of 2.5 x 10(4) cells. Immunotherapy of 3-day lung metastases using tumor-specific T cells and systemic interleukin-2 (IL-2) was ineffective in reducing the number of metastases in vivo. CONCLUSIONS:SCC VII is a poorly immunogenic murinesquamous cell cancer, which represents an ideal model for preclinical testing of immunotherapeutic approaches for patients with SCC of the upper aerodigestive tract. Copyright 2001 John Wiley & Sons, Inc. Head Neck 23: 899-906, 2001.
Authors: D Separovic; J Bielawski; J S Pierce; S Merchant; A L Tarca; G Bhatti; B Ogretmen; M Korbelik Journal: Int J Oncol Date: 2010-12-06 Impact factor: 5.650
Authors: Nithin B Boppana; Jeremy S DeLor; Eric Van Buren; Alicja Bielawska; Jacek Bielawski; Jason S Pierce; Mladen Korbelik; Duska Separovic Journal: J Photochem Photobiol B Date: 2016-03-16 Impact factor: 6.252
Authors: Zipei Feng; Shawn M Jensen; David J Messenheimer; Mohammad Farhad; Michael Neuberger; Carlo B Bifulco; Bernard A Fox Journal: J Immunol Date: 2016-03-18 Impact factor: 5.422
Authors: D Separovic; J Bielawski; J S Pierce; S Merchant; A L Tarca; B Ogretmen; M Korbelik Journal: Br J Cancer Date: 2009-02-24 Impact factor: 7.640